Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and nivolumab monotherapy as maintenance therapy following fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Owonikoko, Taofeek K., Park, Keunchil, Govindan, Ramaswamy, Ready, Neal, Reck, Martin, Peters, Solange, Dakhil, Shaker R., Navarro, Alejandro, Rodríguez-Cid, Jerónimo, Schenker, Michael, Lee, Jong-Seok, Gutierrez, Vanesa, Percent, Ivor, Morgensztern, Daniel, Barrios, Carlos H., Greillier, Laurent, Baka, Sofia, Patel, Miten, Lin, Wen Hong, Selvaggi, Giovanni, Baudelet, Christine, Baden, Jonathan, Pandya, Dimple, Doshi, Parul, Kim, Hye Ryun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078251/
https://www.ncbi.nlm.nih.gov/pubmed/33683919
http://dx.doi.org/10.1200/JCO.20.02212

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078251/
https://www.ncbi.nlm.nih.gov/pubmed/33683919
http://dx.doi.org/10.1200/JCO.20.02212

Ejemplares similares